myrelez 60 mg šķīdums injekcijām pilnšļircē
amdipharm limited, ireland - lanreotīds - Šķīdums injekcijām pilnšļircē - 60 mg
myrelez 90 mg šķīdums injekcijām pilnšļircē
amdipharm limited, ireland - lanreotīds - Šķīdums injekcijām pilnšļircē - 90 mg
myrelez 120 mg šķīdums injekcijām pilnšļircē
amdipharm limited, ireland - lanreotīds - Šķīdums injekcijām pilnšļircē - 120 mg
tecfidera
biogen netherlands b.v. - dimethyl fumarate - multiplā skleroze - imūnsupresanti - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate mylan
mylan ireland limited - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate teva
teva gmbh - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate accord
accord healthcare s.l.u. - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
gaspari nutrition myofusion™ (paziņots 2010.) pulveris
gaspari nutrition - pulveris
slenyto
rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders; autistic disorder - psihoterapija - slenyto ir indicēts, lai ārstētu bezmiegs bērniem un pusaudžiem vecumā 2-18. daļa ar autismu spektra traucējumi (asd) un / vai smits-magenis sindroms, kur gulēt higiēnas pasākumi nav bijuši pietiekami,.